other material
confidence high
sentiment positive
materiality 0.50
Profound Medical touts TULSA data at iMRI Symposium; CAPTAIN shows 2.1x functional preservation vs robotic RP
Profound Medical Corp.
- CAPTAIN randomized trial: whole-gland TULSA patients 2.1x more likely to preserve erectile function and pad-free continence vs robotic prostatectomy (p=0.004); hospitalizations 0.7% vs 6.3%.
- CARE Registry (197 patients, 5 centers, median 24-mo follow-up): median PSA nadir 0.23 ng/mL whole-gland vs 0.60 subtotal vs 1.10 focal; catheterization 13.5 days vs 7 days.
- Mayo Clinic Florida: 58 patients up to 4.5 years; 100% pad-free and 94% leak-free continence, 87.5% potency beyond 12 months; median PSA nadir 0.9 ng/mL; 12% needed secondary treatment.
- Mayo Clinic Rochester: 41 patients, mean PSA fell roughly 62-66% from 7.7 ng/mL through one year; biopsy-confirmed recurrence in 22% (12% in-field, 10% out-of-field).
- Siemens 0.55T Free.Max platform validated: 3D thermometry precision up 40%, targeting accuracy 1.0±0.9 mm; no FDA clearance or commercial availability claimed.